Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and Early Postoperative Cognitive Dysfunction in the Elderly
ChiCTR-IPR-17010496Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in post-operative cognitive decline (POCD) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: ISPOCD test-battery score, Interleukin-6 (IL-6) and 2 more. Started Jan 2017; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
post-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ChiCTR-IPR-17010496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010496.